Biomark Capital

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

BetterDoctor, Inc. is a technology company based in San Francisco, founded in 2011, that focuses on improving healthcare access by providing web and mobile applications for users to find doctors. Its platform allows individuals to search for healthcare providers based on their specific needs and insurance plans, offering a directory of verified doctors. BetterDoctor also serves health plans and systems by validating and delivering accurate provider data through its API, supporting numerous companies and developers in enhancing their healthcare offerings. By enabling real-time appointment scheduling and ensuring the accuracy of doctor information, BetterDoctor aims to simplify the process of finding qualified healthcare professionals, thereby improving patient outcomes. As of June 2018, BetterDoctor operates as a subsidiary of Quest Analytics, L.L.C.

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

i2Dx is developing a multimodal, cloud-based diagnostic platform for the assessment of neurological disorders. The platform will provide quantitative digital assessments of a number of biomarkers that are indicative of brain health with the goal of providing a personalized, longitudinal brain record for healthy individuals and patients.

WhiteGlove Health, Inc. is a mobile healthcare provider based in Austin, Texas, specializing in delivering primary care, preventative medical services, and support for individuals with chronic conditions directly at home and work sites. Established in 2006, the company has expanded its services to major locations including Dallas/Fort Worth, Houston, San Antonio, and Phoenix. WhiteGlove Health focuses on creating a high-quality healthcare experience while simultaneously reducing costs for health plans through decreased insurance claims and minimized unnecessary medical utilization. The clinical team, composed of board-certified nurse practitioners and registered nurses, provides comprehensive care, including at-home visits and telephonic support, particularly for high-risk patients under Medicare and Medicaid. The company’s Value-Based Care division, launched in 2014, emphasizes proactive management to reduce hospital admissions and improve patient outcomes. Additionally, WhiteGlove Health enhances its service offerings through a partnership with Glenridge Healthcare Solutions, which provides advanced analytics and technology solutions, further promoting efficient healthcare delivery across the nation.

WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

HyperMed Imaging, Inc. is a company based in Memphis, Tennessee, that specializes in the development of medical hyperspectral imaging technology for surface tissue oximetry. Founded in 2006, HyperMed focuses on providing advanced solutions for measuring key indicators such as oxyhemoglobin, deoxyhemoglobin, and oxyhemoglobin saturation in superficial tissue, which are crucial for various healthcare applications. The company’s flagship product, OxyVu, received FDA 510(k) approval and is designed to aid in the diagnostic assessment of microvasculature perfusion, particularly in areas such as wound healing, diabetic foot ulcers, and amputation planning. Originally developed for military surveillance, HyperMed's hyperspectral imaging technology offers a sophisticated form of spectroscopy that creates a two-dimensional map of tissue oxygenation, tapping into a multi-billion dollar market for clinical diagnostic applications.

Flexible Stenting Solutions, Inc. is a privately held medical device company specializing in the development and commercialization of advanced flexible stents. Utilizing a proprietary design platform, the company has created a third-generation self-expanding stent specifically engineered to withstand the challenging loading conditions found in the superficial femoral and popliteal arteries. This innovative stent features a unique combination of helically wound struts and flexible coils, resulting in high durability, fatigue resistance, superior radial stiffness, and low chronic outward force. The delivery technology emphasizes simplicity and ease of use for medical professionals. Flexible Stenting Solutions has achieved significant regulatory milestones, including CE Mark authorization for its FlexStent® Femoropopliteal and Biliary Self Expanding Stent Systems in January 2009, followed by 510(k) clearance for the FlexStent® Biliary Self Expanding Stent System in September 2009. These stents are designed to provide substantial benefits for patients suffering from malignant biliary strictures, effectively alleviating symptoms associated with biliary obstruction.

Lentigen Corporation, a biotechnology company, engages in the development and commercialization of gene delivery technologies for human disease. It provides lentiviral vector technology for a range of therapeutic, vaccine, and research applications in biotechnology and medicine. The company offers LG690, a cell therapy for treatment of graft vs hot diseases; LG768, a cancer vaccine for the treatment of leukemia; stem cell therapy to prevent and treat medical disorders; LG631, a treatment that makes chemotheraphy for brain cancer less toxic; LG889, a steam cell therapy for hemophilia; LG611, an exact strain matched influenza vaccine for pandemic flu; LG811, an exact strain matched influenza vaccine for seasonal flu; LG747, a biosimilar erytho poieitin; and LG888, a novel factor VIII protein therapy for Hemophilia A. Lentigen Corporation was founded in 2004 and is headquartered in Gaithersburg, Maryland.

MabVax Therapeutics is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative anti-cancer immunotherapies. The company leverages two main technology platforms: one involves proprietary vaccines developed at Memorial Sloan-Kettering Cancer Center, with two lead cancer vaccines currently in Phase II clinical trials targeting soft tissue sarcoma and ovarian cancer, both of which have received substantial federal grant support. The second platform is an internally developed human antibody discovery system, which focuses on the immune responses from patients who have been vaccinated against specific cancers. MabVax's leading human antibody candidate is in preclinical evaluation for potential applications in treating colon, pancreatic, and breast cancers, also backed by federal funding. The company aims to address significant unmet needs in cancer treatment through its innovative approaches and pipeline of human monoclonal antibody products.

MabVax Therapeutics is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative anti-cancer immunotherapies. The company leverages two main technology platforms: one involves proprietary vaccines developed at Memorial Sloan-Kettering Cancer Center, with two lead cancer vaccines currently in Phase II clinical trials targeting soft tissue sarcoma and ovarian cancer, both of which have received substantial federal grant support. The second platform is an internally developed human antibody discovery system, which focuses on the immune responses from patients who have been vaccinated against specific cancers. MabVax's leading human antibody candidate is in preclinical evaluation for potential applications in treating colon, pancreatic, and breast cancers, also backed by federal funding. The company aims to address significant unmet needs in cancer treatment through its innovative approaches and pipeline of human monoclonal antibody products.

Spectral Image, Inc. is an early-stage medical device company based in Tampa, Florida, established in 2007. The company specializes in developing advanced imaging technology for biomedical applications. Currently operating in stealth mode, Spectral Image is prioritizing the protection of its intellectual property before revealing specific details about its innovations. In 2008, the company planned to begin a pilot study of its technology at a leading medical facility in the United States, marking a significant step in its development and potential market introduction.